Oxantium Leads Series B Investment in Advanced RF Device Maker

RF Nano Corporation(TM), the leader in carbon nanotube analog electronics announces that it has raised $8 Million in Series B venture capital to accelerate the development of its breakthrough technology. Washington D.C. based Oxantium Ventures lead the round and Oxantium Managing Director Dr. Richard Wirt will join the RF Nano Board of Directors. Okapi Ventures, RF Nano’s series A lead investor, also participated in this round.

”Building on the outstanding work of Professor Peter Burke at UCI, RF Nano has developed low cost manufacturing processes and extended its leadership position in the application of carbon nanotubes to high performance analog electronics,” said Steffen McKernan, Chief Executive Officer and co-founder of RF Nano. ““We are very pleased that Dr. Richard Wirt and Oxantium are joining RF Nano. Even before closing this financing, the Oxantium team has added significant value to our business. Their deepening engagement will accelerate delivery of our products and help us drive the creation of a future of analog and mixed-signal systems uniquely enabled by RF Nano’s technology.”

“Oxantium is pleased to be the lead investor for this round of investment in RF Nano," said Oxantium’s Richard Wirt. "RF Nano’s technology will enable a new generation of robust, high bandwidth wireless devices. As RF Nano harnesses the fundamental promise of carbon nanotubes, the semiconductor world will be forever changed."

"We continue to be enthusiastic investors in RF Nano. They have built a strong team with deep industry experience focused on delivering against the tremendous potential for utilizing carbon nanotubes in RF applications," said Marc Averitt of Okapi Venture Capital. "Initial feedback from major players in the RF marketplace confirms our belief in the game changing nature of RF Nano's product pipeline."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.